EcoDrugPlus

Nuclear Receptor Subfamily 3, Group C, Member 1 (Glucocorticoid Receptor)

Ensembl ID : ENSORLG00000006022
Gene Symbol: NR3C1
3 Cross references
205 Possible Orthologues:

Nuclear Receptor Subfamily 3, Group C, Member 2

Ensembl ID : ENSORLG00000007530
Gene Symbol: NR3C2
3 Cross references
209 Possible Orthologues:

Nucleotide-Binding Oligomerization Domain Containing 2

Ensembl ID : ENSORLG00000013891
Gene Symbol: NOD2
4 Cross references
166 Possible Orthologues:

Opiate Receptor-Like 1

Ensembl ID : ENSORLG00000026714
Gene Symbol: OPRL1
4 Cross references
188 Possible Orthologues:

Opioid Receptor, Delta 1a

Ensembl ID : ENSORLG00000008447
Gene Symbol: OPRD1A
4 Cross references
191 Possible Orthologues:

Opioid Receptor, Kappa 1

Ensembl ID : ENSORLG00000017839
Gene Symbol: OPRK1
4 Cross references
197 Possible Orthologues:

Opioid Receptor, Mu 1

Ensembl ID : ENSORLG00000004921
Gene Symbol: OPRM1
4 Cross references
214 Possible Orthologues:

Oxytocin Receptor A

Ensembl ID : ENSORLG00000000719
Gene Symbol: OXTRA
3 Cross references
191 Possible Orthologues:

P21 Protein (Cdc42/rac)-Activated Kinase 4

Ensembl ID : ENSORLG00000001503
Gene Symbol: PAK4
4 Cross references
166 Possible Orthologues:

Parathyroid Hormone 1 Receptor

Ensembl ID : ENSORLG00000017615
Gene Symbol: PTH1R
4 Cross references
196 Possible Orthologues:

Peroxisome Proliferator-Activated Receptor Alpha A

Ensembl ID : ENSORLG00000011091
Gene Symbol: PPARAA
3 Cross references
383 Possible Orthologues:

Peroxisome Proliferator-Activated Receptor Alpha B

Ensembl ID : ENSORLG00000002413
Gene Symbol: PPARAB
4 Cross references
396 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).